Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
http://link.springer.com/article/10.1007/s00432-018-2764-8/fulltext.html
Reference18 articles.
1. Albain KS, Crowley JJ, Livingston RB (1991) Long-term survival and toxicity in small cell lung cancer expanded Southwest Oncology Group experience. Chest 99:1425–1432
2. Demedts I, Vermaelen K, Van Meerbeeck J (2010) Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 35:202–215
3. Hong W, Li H, Jin X, Shi X (2017) P1.07-053 apatinib for chemotherapy-refractory extensive stage SCLC: results from a single-center retrospective study. J Thorac Oncol. https://doi.org/10.1016/j.jtho.2016.11.965
4. Kalemkerian GP et al (2013) Small cell lung cancer. J Natl Compr Cancer Netw 11:78–98
5. Leyvraz S et al (1999) Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: a feasibility study by the European Group for blood and marrow transplantation. J Clin Oncol 17:3531–3539
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Fibrosis-associated DDR1 downregulation contributes to a better prognosis in oral squamous cell carcinoma associated with oral submucous fibrosis;Medical Hypotheses;2023-05
2. Efficacy and safety of anlotinib as maintenance therapy after induction chemotherapy in extensive-stage small-cell lung cancer;Anti-Cancer Drugs;2022-12-23
3. A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer;Cancer Medicine;2022-09-09
4. Parotid metastases from primary lung cancer: Case series and systematic review of the features;Frontiers in Oncology;2022-08-25
5. Apatinib as maintenance therapy following standard first‐line chemotherapy in extensive disease small cell lung cancer: A phase II single‐arm trial;Thoracic Cancer;2022-01-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3